Bacterial resistance to antibiotics is a global health threat. Creative collaboration is the key to successfully meeting the challenge.

Thursday, 17 November 2011

As a company with a long-standing commitment to collaboration, we welcome the level of engagement demonstrated by today’s European Commission announcement regarding plans to develop an innovative and collaborative approach to finding new antibiotics. While the full details of the proposed Innovative Medicines Initiative need to be fleshed out, we are excited about the possibility of new approaches to collaborative working and will remain committed to being an active partner in the global effort to meet the challenge of bacterial resistance.

Tomorrow’s annual European Antibiotic Awareness Day is a powerful reminder that steady rise of drug-resistant bacteria is an imminent and urgent threat to public health. We see today’s announcement as a significant and positive step forward in meeting this challenge.

Our ongoing work in this area

Scientist working at AstraZeneca R&D Boston (MA)

AstraZeneca has continued to invest in antibiotic research over the last 20 years and today. We have leading capabilities and two antibiotics in our range of marketed medicines, including a leading cabapenem anti-bacterial effective against multi-drug-resistant bacteria. Our ongoing efforts to improve our pipeline of new products include a $100 million investment in a new facility in Boston, US focused on anti-bacterial research.

We know we can’t do it alone – the challenges are too great. Alongside the work we do in our own laboratories, we partner with other organisations, sharing skills, resources and insights to broaden the platform for successful innovation that will meet the growing need for new ways of treating multi-drug resistant bacteria.

Read more

How collaborative working can achieve the right safety profile

AZ scientists Mark Anderton and Ray Finlay discuss their role in re-designing an oncology compound

Achieving the right balance of benefit-risk is crucial; our job is to identify, characterise and eliminate molecules with negative benefit-risk balance as early and as quickly as possible.

Read the latest post on LabTalk


Read the latest blogs from our scientists working in our oncology portfolio

Oncology_compound_shows_THM 30 May 2014

Oncology compound shows how collaborative working can achieve the right safety profile

Driving open innovation across Asia THM 22 May 2014

AstraZeneca is driving open innovation across Asia